Anti-Glycation Methods and Compositions

ABSTRACT

The present invention comprises compositions that provide anti-glycation activity comprising a mineral extract composition or a mogroside/mineral extract composition or a mogroside composition. Such compositions are useful for methods of preventing, treating and inhibiting the effects of glycation in the body. The methods of the present invention comprise use of anti-glycation composition for the treatment and prevention of glycation related conditions including diabetes, atherosclerosis, arthritis, mental conditions and vision impairment.

RELATED APPLICATIONS

The present invention claims the priority of U.S. Provisional PatentApplication No. 60/998,316, filed Oct. 10, 2007, and U.S. ProvisionalPatent Application No. 61/079,826, filed Jul. 11, 2008, each of which isincorporated herein in its entirety.

TECHNICAL FIELD

The present invention relates to compositions used to treat or preventglycation events and related pathologies in humans and animals. Moreparticularly, the invention relates to compositions havinganti-glycation activities.

BACKGROUND OF THE INVENTION

Glycation or non-enzymatic glycosylation involves reaction of aminogroups of proteins, lipids, or nucleic acids with sugar aldehyde or ketogroups to produce modified amino groups and eventually forming advancedglycosylation end-products (AGE). Glycation may be the first step in aseries of slow reactions in the body known as Amadori reactions, Schiffbase reactions, and Maillard reactions and lead to advanced glycationendproducts (AGEs). Although glycation is slow in vivo, the glycationproducts may be reactive, or may have long-lasting effects and thepresence of AGE is related to ageing and pathological conditions. Inphysiological conditions where there is an abundance of sugar moleculesavailable for reaction, such as those where sugar levels are elevated,e.g. diabetes, glycation effects may be more pronounced. Some AGEs arebenign, but others are more reactive, and are implicated in manyage-related chronic diseases such as, type II diabetes mellitus,cardiovascular diseases, Alzheimer's disease, cancer, peripheralneuropathy, and other sensory losses such as deafness and blindness.Glycation also plays a role in lipid and RNA/DNA modifications.

Glycated substances are eliminated from the body slowly, since the renalclearance factor is only about 30%. This fact is used to provide amethod of testing for sugar levels in diabetics. Red blood cells have alifespan of 120 days and are easily accessible for measurement of recentincreased presence of glycating product. The glycated hemoglobin level,also known as HbA1c, is determined and indicates the level of glycationoccurring in the person.

Currently, aminoguanidine is used to slow down glycation by reactingwith sugars and blocking the Amadori reactions. Aminoguanidine canreduce both in vitro and in vivo glucose-derived AGE. Aminoguanidine, anucleophilic hydrazine compound, is currently being studied for use astreatment for AGE complications in diabetes. Additional drugs thatinhibit AGE formation or disrupt already formed AGEs (e.g.,AGE-breakers) are also under active investigation. For example, areversal of vascular inelasticity leading to improvement of systolichypertension and severe heart failure has been reported withAGE-breakers.

Diabetes is a metabolic disorder caused by a deficiency of insulin andis generally diagnosed by an increased blood glucose level. The disorderis characterized by a reduced glucose uptake of the insulin-dependenttissues. The disorder can be controlled by insulin injections but thelong-term complications for diabetics include pathologies in the eye(cataractogenesis and retinopathy), kidney (nephropathy), neurons(neuropathy) and blood vessels (angiopathy and artherosclerosis).Glycation plays a role in the pathologies associated with diabetes.

Studies have shown that AGE may have a role in the development ofatherosclerosis. Monocytes have AGE specific receptors (RAGE) andrespond when stimulated by releasing cytokines. Minor injury to theblood vessel wall may expose sub-endothelial AGE, promote theinfiltration of monocytes and initiate the development ofatherosclerotic lesions. Circulating lipoproteins can also undergoglycation, which are then taken up by endothelial cells at a faster ratethan non-glycated lipoprotein.

Intake of compositions that can counteract the long-term effects of AGEformation and prevent or treat AGE-related pathologies would bebeneficial. Providing such compounds in easily consumed products, suchas beverages or sweetener compositions, would be useful in theprevention or treatment of glycation related conditions.

SUMMARY

The present invention comprises methods and compositions for glycationtreatments and prevention. The compositions of the present inventioncomprise mineral extract compositions that are useful for inhibitingglycation reactions in humans or animals, and for preventing andtreating glycation-related conditions. Compositions of the presentinvention comprise mineral extract compositions, mogroside/mineralextract compositions, and mogroside compositions as described herein.Methods of the present invention comprise methods of treating orpreventing glycation-related conditions comprising providing aneffective amount of a mineral extract composition, a mogroside/mineralextract composition or a mogroside composition to prevent or reduceglycation events occurring in a human or animal.

Mineral extract compositions, mogroside/mineral extract compositionsand/or mogroside compositions are provided or administered to subjects,humans or animals, alone or in combination with other components, toform anti-glycation compositions. For example, a mineral extractcomposition, a mogroside/mineral extract composition or a mogrosidecomposition of the present invention may be combined with a foodstuff orbeverage to provide an anti-glycation composition that is consumed bythe subject. Effective amounts of anti-glycation compositions, forexample, inhibit the formation of glycation products such as AGEs, andprevent or treat conditions related to glycation events in the body.Such glycation-related conditions include, but are not limited to,diabetes mellitus, cardiovascular diseases, Alzheimer's disease, cancer,peripheral neuropathy, and other sensory losses such as deafness, renaldysfunction, and blindness. Compositions of the present inventioncomprise a mineral extract composition, a mogroside/mineral extractcomposition or a mogroside composition in combination with compounds orcompositions that have a sweet taste or are perceived as being sweettasting, to form anti-glycation sweetener compositions.

DESCRIPTION OF FIGURES

FIG. 1 is a graph showing the results of three mineral extractcompositions in the anti-glycation assay.

FIGS. 2 A and B are graphs showing the effects of mineral extractcomposition on mitochondrial metabolism. A: increase of themitochondrial activity in total cell population, B: increase of themitochondrial activity on a per cell basis.

FIG. 3 is a graph showing the effect of a mineral extract composition ontype I collagen production by human cells

FIG. 4 is a graph showing the activity of mineral extract composition onmetalloproteinase activity, in vitro.

FIG. 5 is a graph showing the collagen stimulatory activity ofcompositions of the present invention.

FIGS. 6A and B are graphs showing the metabolism stimulatory activity ofcompositions of the present invention.

FIG. 7 is a graph showing the glycation inhibitory activity ofcompositions of the present invention.

DETAILED DESCRIPTION

The present invention comprises compositions and methods of treating orpreventing complications and pathologies of conditions related to thepresence of glycated molecules such as glycated proteins, lipids ornucleic acids. Glycation-related conditions comprise conditions in thebodies of humans or animals that are due to or related to the presenceof glycated proteins, lipids, and nucleic acids, and include, but arenot limited to, inflammatory responses, atherosclerosis, Alzheimer'sdisease, diabetes, cancer, cardiovascular diseases, and other AGE- andRAGE-related conditions. AGE (advanced glycation end-products) and theirreceptors, RAGE (receptor for advanced glycation end-products) have beenimplicated in conditions as diverse as cardiovascular disease anddiabetes. AGEs are causative of multiple long term loss of cellularfunction and eventual disease states. In essence, sugar-proteincomplexes become chemically cross-linked and degrade normal cellularfunction, while promoting free radical damage.

The present invention comprises compositions and methods that treat orprevent glycation-related conditions. Compositions of the presentinvention comprise mineral extract compositions, mogroside/mineralextract compositions, and mogroside compositions as described herein.Methods of the present invention comprise providing an effective amountof a mineral extract composition or a mogroside/mineral extractcomposition or a mogroside composition to prevent or reduce glycationevents occurring in the subject or to treat or prevent glycation-relatedconditions in humans or animals. Compositions comprising a mineralextract composition or a mogroside/mineral extract composition or amogroside composition are referred to herein as anti-glycationcompositions, but this reference is not intended to limit the activitiesof the compositions.

Advanced Glycation End-Products (AGEs) have been implicated as criticalfactors affecting health, wellness, and longevity, particularly inassociation with inflammation and other disease states. Glycation is thefirst step in a complex series of non-enzymatic reactions in the bodyknown as Amadori reactions, Schiff base reactions, and Maillardreactions, which lead to AGE formation. A characteristic of certainreactive or precursor AGEs is the formation of covalent crosslinking ofproteins, which alters their structure and function, and is found in thecellular matrix, basement membranes, red blood cells, and vessel-wallcomponents. Other major features of AGEs relate to their interactionwith a variety of cell-surface AGE-binding receptors (RAGE), leading toactivation and pro-oxidant, pro-inflammatory events.

A large body of evidence suggests that AGEs are important pathogeneticmediators of almost all diabetes complications, conventionally groupedinto micro- or macroangiopathies. For instance, AGEs are found inretinal vessels of diabetic patients, and their levels correlate withthose in serum, as well as with severity of retinopathy. AGEs are nowimplicated in a vast array of age related degradations from coronarydisease to skin aging. Some AGEs are benign, but others are morereactive than the sugars they are derived from, and are implicated inmany age-related chronic diseases such as: diabetes mellitus where betacells are damaged, cardiovascular diseases in which the endothelium,fibrinogen and collagen are damaged, Alzheimer's disease wherein amyloidproteins are side products of the reactions progressing to AGEs, cancerwith its release of acrylamide and other side products, peripheralneuropathy and other sensory losses such as deafness due todemyelination, renal dysfunction and blindness which occur because ofmicrovascular damage. This range of diseases shows the extent of theeffects of advanced glycation end products interfering with molecularand cellular functioning throughout the body and the other side effectsassociated with AGE, such as the release of highly-oxidizing sideproducts such as hydrogen peroxide.

Glycated substances are eliminated from the body slowly, and the renalclearance factor is only about 30%. As a consequence, long-lived cells(such as neurons), long-lasting proteins (such as eye crystalline andcollagen), and DNA may accumulate substantial damage over time.Metabolically-active cells such as those in kidney's glomeruli, retinacells in the eyes, and beta cells (insulin-producing) in the pancreasare also at high risk of damage. The endothelial cells of the bloodvessels are damaged directly by glycation, which has implications inatherosclerosis. Atherosclerotic plaque tends to accumulate at areas ofhigh blood flow due to the increased presentation of sugar molecules,and glycation end-products at these points. Damage by glycation resultsin stiffening of the collagens in the blood vessel walls, andcontributes to high blood pressure. Glycation also causes weakening ofblood vessel walls, which may lead to micro- or macro-aneurisms, whichin turn, if formed in the brain, may lead to strokes.

In addition to endogenously formed AGE, AGE can also be introduced inthe body from exogenous sources. Exogenous AGE may be consumed as“dietary” or “preformed” AGE. These are formed when sugars are cookedwith proteins or fats. Tobacco smoke, for example, is a well-knownexogenous source of AGEs. The combustion of various pre-AGEs in tobaccoduring smoking gives rise to reactive and toxic AGEs. Serum AGEs orLDL-linked AGEs are significantly elevated in cigarette smokers.Diabetic smokers, as a result, are reported to exhibit greater AGEdeposition in their arteries and ocular lenses.

Aminoguanidine, an inhibitor of AGE formation, has been shown to preventretinopathy in diabetic animals. Also, AGEs accumulate in peripheralnerves of diabetic patients and use of anti-AGE agents improves nerveconduction velocities and corrects neuronal blood flow abnormalities.

Atherosclerosis is significantly accelerated in diabetic patients and isassociated with greater risk of cardiovascular and cerebrovascularmortality. Preclinical and clinical studies have shown that AGEs play asignificant role in the formation and progression of atheroscleroticlesions. Increased AGE accumulation in the diabetic vascular tissues hasbeen associated with changes in endothelial cell, macrophage, and smoothmuscle cell function. In addition, AGEs can modify LDL cholesterol insuch a way that it tends to become easily oxidized and deposited withinvessel walls, causing streak formation and, in time, atheroma.AGE-crosslink formation results in arterial stiffening with loss ofelasticity of large vessels.

AGEs form at a constant but slow rate in the normal body, starting inearly embryonic development, and accumulate with time. However, theirformation is markedly accelerated with aging or with increased exposureto the sugar sources, such as glucose, fructose and galactose.

It has been surprisingly found that a mineral extract composition or amogroside/mineral extract composition or a mogroside compositiondescribed herein demonstrates anti-glycation properties comparable to orbetter than aminoguanadine. Minerals are involved in the body in a vastarray of complex reactions, most of which are dependent on mineralchemical characteristics. Minerals and electrolytes maintain fluid andacid-base balance and they are chemically active as cofactors incountless enzyme-catalyzed reactions. The mineral extract compositionsor mogroside/mineral extract compositions or mogroside compositions ofthe present invention may comprise dry powders, liquid formulations,food compositions, cosmetic compositions, and compositions administeredby injection. The compositions may be added to a second composition toform a combined composition to provide the anti-glycation activity foundin a mineral extract composition or a mogroside/mineral extractcomposition or a mogroside composition to the second composition.

Compositions of the present invention comprise mineral extractcompositions. The method of making such compositions is taught in U.S.Patent Publication No. 2005/0118279, which is herein incorporated in itsentirety. Briefly, to make a mineral extract composition of the presentinvention a soil from a suitable site, comprising the elements asdescribed in U.S. Patent Publication No. 2005/0118279, is collected andsubjected to the aqueous extraction process described therein to producea liquid mineral element composition containing mineral elements whichmay be dried to produce a dry powder mineral element composition.

Both the liquid mineral extract composition and the dry powder mineralextract composition comprise the mineral elements of a comprehensivemineral composition, as described in U.S. Patent Publication No.2005/0118279. Both liquid and dry powder mineral extract compositionsproduced by the procedures described herein generally contain a minimumof 8 macro mineral elements and a minimum of 60 micro mineral elements.

Physical testing and analysis was also conducted on the liquid and drymineral element compositions. Typical specifications of the liquidmineral extract composition range in color and may be from yellow toamber brown, and contain between 1 to 10% by weight of mineral elements,or from 3-5% by weight of mineral elements. The liquid mineral extractcomposition is acidic with a pH ranging from 2.5-4.5, or from 2.5-3.5.The liquid mineral extract composition can be dried to produce ananhydrous powder. The anhydrous powder may range in color fromlight-off-white to brown, or from yellow to golden amber, is insolublein non-polar solvents such as hydrophobic liquids (oil and fats), isinsoluble in alcohol, and is readily soluble, yet non-swelling, in waterand hydro-alcoholic solutions at concentrations of 1 to 5% by weight, orat concentrations of 3-5% by weight. The dry powder is partially solubleor capable of being partially suspended in polar solvent insupersaturated solutions.

Both liquid and dry mineral extract compositions produced by theprocedures described herein may contain a minimum of 8 macro mineralelements and a minimum of 60 micro mineral elements. The micro mineralelements include trace and rare earth mineral elements.

For example, the dry mineral extract composition may compriseconcentrations ranging from 0.0001-20.00% by weight percent, from0.001%-10%, from 0.1% to 20%, from 1% to 20%, from 1% to 10%, from 5% to10%, from 10-20%, from 10% to 15%, from 15% to 20%, from 1% to 5%, from5% to 15%, by weight percent, the macro mineral elements of calcium,chlorine, magnesium, manganese, phosphorous, potassium, silicon, andsodium; and, will preferably contain at least sixty micro mineralelements at concentrations ranging from 0.00001-3.0% by weight percent,from 0.0001-1%, from 0.001% to 1%, from 0.01% to 3%, from 0.1% to 3.0%,by weight percent. The micro mineral elements include aluminum,antimony, arsenic, barium, beryllium, bismuth, boron, bromine, cadmium,cerium, cesium, chromium, cobalt, copper, dysprosium, erbium, europium,fluorine, gadolinium, gold, hafnium, holmium, iodine, indium, iridium,iron, lanthanum, lead, lithium, lutetium, mercury, molybdenum,neodymium, nickel, niobium, palladium, platinum, praseodymium, rhenium,rhodium, rubidium, ruthenium, samarium, scandium, selenium, silver,strontium, sulfur, tantalum, terbium, tellurium, thallium, thorium,thulium, tin, titanium, tungsten, vanadium, ytterbium, yttrium, zinc,and zirconium.

The extraction process used to make the mineral extract compositions ofthe present invention normally does not introduce any minerals as partof the extraction process. Therefore, the source materials, the originalclay or other soil that is processed through the extraction method,likely include aluminum silicates and other metal silicates in naturethat have been naturally enriched with multiple detectable minerals. Ifa mineral element is identified and quantified in the aqueous liquidextract, generally, it will be identified and quantified in the drypowdered extract in much higher concentrations as a result of dryingprocess or volume reduction.

For example, an extract composition produced using the soil andextractions methods described in U.S. patent application Ser. No.10/725,729, incorporated herein by reference, was tested by independentanalytical testing for conducting chemical analysis using standardtechniques of identification and quantification for both dry and liquidforms of the mineral extract composition. The results of testingperformed at Teledyne Wah Chang Laboratories in Huntsville, Ala.,utilizing scientifically accepted and standard equipment such astitration, inductively coupled plasma, mass spectrometry, and atomicabsorption equipment resulted in the mineral element quantification dataset forth below in TABLE I for an aqueous mineral extract compositionand from the dry mineral extract composition that resulted when theaqueous mineral extract composition was dried to produce a powder.

TABLE I Mineral Extract Composition Concentration in aqueousConcentration in Element liquid composition dry powder Macro MineralElements Calcium 2900 ppm   8% Chlorine 170 mg/ml  0.84%* Magnesium 460ppm 0.95% Phosphorous 0.2 g/L 0.43% Potassium 220 mg/L  1.2% Silicon 130mg/L 0.36% Sodium 720 mg/L  2.0% Micro Mineral Elements Aluminum 540 ppm0.65% Antimony 460 ppb 16.0 ppm Arsenic 11 ppm 3.1 ppm Barium 340 ppb11.0 ppm Beryllium 0.29 ppm .01 ppm Bismuth <50 ppb <1.00 ppm Boron 2.0mg/L 72.0 ppm Bromine *Present as part of Chlorine assay Cadmium <50 ppb1.10 ppm Total Organic Carbon 12 g/L Trace Cerium 1600 ppb 68.00 ppmCesium 82 ppb 2.00 ppm Chromium 1.8 ppm 5.00 ppm Cobalt 0.25 ppm 1.00ppm Copper 0.09 ppm <1.00 ppm Dysprosium 230 ppb 9.00 ppm Erbium 150 ppb6.00 ppm Europium <50 ppb 2.00 ppm Fluorine *Present as part of Chlorineassay Gadolinium 220 ppb 9:00 ppm Gallium 70 ppb 2.40 ppm Germanium <50ppb <1.00 ppm Gold <50 ppm <1.00 ppm Hafnium <0.5 mg/L 5.00 ppm Holmium<50 ppb 2.00 ppm Iodine *Present as part of Chlorine assay Indium <50ppb Trace Iron 730 ppm 28.00 ppm Lanthanum 650 ppb 28.00 ppm Lead <50ppb <1.O0 ppm Lithium 0.9 mg/L <1.00 ppm Lutetium <50 ppb <1.00 ppmMercury Trace <1.00 ppm Molybdenum 3200 ppb 120.00 ppm Neodymium 1000ppb 45.00 ppm Nickel 0.74 ppm 2.00 ppm Niobium 96 ppb 3.00 ppm Palladium<500 ppb <1.00 ppm Platinum <50 ppb <1.00 ppm Praseodymium 290 ppb 10.00ppm Rhenium <50 ppb <1.00 ppm Rhodium <50 ppb <1.00 ppm Rubidium 360 ppb11.00 ppm Ruthenium <50 ppb <1.00 ppm Samarium 250 ppb 10.00 ppmScandium <400 ppb 4.00 ppm Selenium 0.63 mg/L 21.00 ppm Silver <0.02 ppm<5.00 ppm Strontium 14000 ppb 420.00 ppm Sulfur 1.1 g/L  1.8% Tantalum<50 ppb <1.00 ppm Terbium <50 ppb 2.00 ppm Tellurium <50 ppb <1.00 ppmThallium <50 ppb 1.00 ppm Thorium 640 ppm 22.00 ppm Thulium <50 ppb 1.00ppm Tin <50 ppb <1.00 ppm Titanium 9.34 ppm 210.00 ppm Tungsten 52 ppb17.00 ppm Vanadium 4.3 ppm 14.00 ppm Ytterbium 140 ppb 6.00 ppm Yttrium1300 ppb 61.00 ppm Zinc 1.2 ppm 14.00 ppm Zirconium 2.0 mg/L 62.00 ppm

The mineral extract compositions set forth above in Table I wereproduced from naturally occurring soil the analysis of which isreflected below in Table II.

TABLE II Analysis of Naturally Occurring Soil Macro Mineral ElementsConcentration in ppm by weight unless Element noted as % (for weightpercent) Silicon 25.0% Aluminum 9.3% Potassium 4.8% Magnesium 0.83%Sulfur 1.6% Iron 1.6% Calcium 4.1% Titanium 0.23% Sodium 0.138%Manganese 150 Gallium 25 Molybdenum 61 Germanium 25 Iodine 7 Bromine 5.2Tungsten 8.1 Hafnium 2.0 Tantalum 0.50 Zirconium 10 Arsenic 0.2 Antimony29 Selenium 4.1 Zinc 20 Samarium 3.5 Holmium 1.1 Terbium .62 Iridium .51Lutetium .45 Chromium 70 Lanthanum 18 Ruthenium 7.8 Yttrium 1.2 Indium.38 Lead (under) 17 Niobium 2.89 Carbon .19 Hydrogen .05 Nitrogen .03Scandium 3.7 Cobalt 4.8 Ytterbium 1.4 Strontium 240 Barium 390 Gold .68Europium .49 Neodymium 20 Cerium 40 Cesium 183 Thorium Above 100 UraniumAbove 100 Nickel 60 Beryllium .10 Bismuth 14.3 Boron 7 Cadmium 1.12Chloride 6100 Copper 2.2 Fluoride 3.85 Lithium 1.44 Mercury 0.166Palladium 0.74 Phosphate 320 Platinum 0.08 Rhodium 0.44 Rubidium 36.5Silver 0.3 Tellurium 0.1 Thulium 0.65 Tin 0.44 Vanadium 8 Dysprosium 4.0Praseodymium 2.0 Thallium 10 Rhenium 1.0 Erbium 2.0 Oxygen 0.2

Once a desirable naturally occurring soil or soil combination isobtained, the soil(s) is subjected to the extraction process describedby U.S. patent application Ser. No. 10/725,729. Clay soils, mixtures ofclay soils, or mixtures of clay soil(s) and leonardite are preferred inthe practice of the invention. One reason such soil combinations arepreferred is that such soils can be high in the mineral elements deemedimportant in the practice of the invention. As noted, it is preferredthat mineral extract compositions produced in accordance with theinvention include at least eight macro mineral elements and at leastsixty micro mineral elements.

The first step in determining whether a clay soil is acceptable as asource material is to determine of arsenic, lead, mercury, and cadmiumare each present in acceptably small concentrations. An aspect of thepresent invention comprises compositions having the concentration ofeach of these elements in lower amounts than the concentrations shownbelow in Table III.

TABLE III Maximum Desired Concentrations of Toxic Elements MaximumDesired Soil Element Concentration in ppm or ppb Arsenic 0.2 ppm Lead0.17 ppb Mercury 0.116 ppm Cadmium 1.12 ppm

TABLE IV Preferred Minimum Concentrations of Selected Rare EarthElements in Naturally Occurring Soil Preferred Minimum Soil ElementConcentration in ppm Cerium 40 Praseodymium 2 Neodymium 20 Samarium 3.5Europium 0.49 Terbium 0.62 Dysprosium 4 Holmium 1 Erbium 2 Thulium 0.65Ytterbium 1.2 Lutetium 0.45

The concentration of the elements listed in Table IV can vary asdesired, but, as noted, it is desirable to have at least theconcentration of each element as noted in Table IV. Source material soilfor composition of the present invention may or may not comprise one orall of the rare earth elements listed in Table IV. For example, alanthanum concentration of at least eighteen ppm and a scandiumconcentration of at least three and seven-tenths ppm may be found in asource material soil. Concentrations of promethium and gadolinium mayalso be found. Source material soil for composition of the presentinvention may or may not comprise at least ten rare earth elements, atleast twelve, or more rare earth elements and optionally includelanthanum and scandium. Though not wishing to be bound by any particulartheory, it is theorized that the presence of rare earth elements in thesoil, and in the mineral extract compositions derived from the sourcematerial soil, is believed to be useful in improving the efficacy of themineral extract compositions when ingested or when transdermallyabsorbed by the body.

Once a clay soil or clay and soil combination is provided or is combinedto yield the mineral elements, as taught by U.S. patent application Ser.No. 10/725,729, the source material soil is subjected to the extractionprocess as taught by U.S. patent application Ser. No. 10/725,729, toyield the mineral extract compositions comprised in the anti-glycationcompositions of the present invention.

In general, the extraction of the source material soil uses thefollowing steps. Water, typically purified using known methods such asreverse osmosis, is added to citric acid and the source material soil ina mixing tank. The amount of citric acid (or of phosphoric acid or otheredible acid(s)) or combinations thereof, may be in the range of 0.25% to7.5% of the weight of water utilized, but typically is in the range of1.0% to 2.0%. The water, citric acid and source material soil, form aslurry and is gently agitated (for example, with a blade slowly rotatingat from one to ten RPM) for about an hour, although the agitation timecan vary as desired. The slurry from the tank is directed into asettling tank to permit particulates to settle downwardly out of theslurry. The slurry is maintained in the settling tank for any desiredlength of time, in the range of about one to ten days. As the length oftime that the slurry is maintained in the settling tank increases, theamount of liquid that can be drawn out of the tank and sent to a coolingtank or concentrator increases and the amount of solids that havesettled to the bottom of the tank increases. Additives can be used tofacilitate the settling of solids from slurry. After the slurry hasresided in settling tank for the desired period of time, liquid is drawnout of the tank to a cooling tank, or directly to the concentrator. Thesolids on the bottom of tank can be reprocessed, discarded, or can beotherwise utilized.

The cooling tank cools the fluid from the settling tank to a temperaturein the range of 40-70° F. (5 to 21° C.). Cooled liquid is sent to theconcentrator.

The concentrator removes water from the cooled liquid. This may beaccomplished using known methods such as a thin film composite reverseosmosis system or evaporation. The resulting concentrate liquid,comprising the minerals extracted from the original slurry, is directedto a cooling tank or to a dryer, depending if storage or furtherprocessing is desired. The cooling tank cools the concentrate liquid to40 to 70° F. (5 to 20° C.) to prevent the growth and yeast and mold.

The concentrate liquid produced by concentrator has a pH ofapproximately 3. The concentrate liquid typically includes from three totwelve percent by weight mineral elements, i.e. if the mineral elementsare separated from the concentrate liquid, a dry material is producedthat has a weight equaling about 3% to 12% by weight of the concentrateliquid. The pH of the concentrate liquid is adjusted by varying theamount of citric acid or other edible acid and/or alkaline or acidicsoil added to the mixing tank and is in the range of pH 2.0 to pH 5.0,preferably pH 2.5 to pH 3.5. The pH of the concentrate liquid (and drypowder or other material produced therefrom) preferably is less than pH4.5. A mineral extract concentration of at least eight percent may beprovided for injection into a dryer. Any desired drying system can beutilized, such as a tower into which the concentrate liquid is sprayedto produce a powder.

Anti-glycation compositions of the present invention may comprise amineral extract composition, such as that shown in Table 1, or amogroside/mineral extract composition or a mogroside composition,combined or admixed with a second component. A mineral extractcomposition has activity for energy production, and collagen growthstimulation. Other activities of a mineral extract composition may befound in U.S. patent application Ser. Nos. 10/725,729, 11/472,536 and11/638,311, each of which is herein incorporated in its entirety. Asecond component of the anti-glycation compositions may be a liquid or adry component, to form liquid or dry compositions. Liquid anti-glycationcompositions comprise a mineral extract composition, a mogroside/mineralextract composition or a mogroside composition, in either a dry powderform or a liquid form, and a liquid, including but not limited to,water, which may be still or carbonated, and other ready to drink orready to mix beverages, including but not limited to coffees, teas,energy drinks, juices, milks, and plant liquids such as soy products,sugar cane products, coconut products, protein drinks, meal replacementdrinks, and alcohol containing products such as beer and wine. Liquidanti-glycation compositions may comprise pharmaceutical, nutraceuticalor dietary supplement compositions in combination with a mineral extractcomposition. For example, an anti-glycation composition may compriseliquid pharmaceutically acceptable syrups, excipients, fillers or otherknown pharmaceutical formulations in combination with a mineral extractcomposition, a mogroside/mineral extract composition or a mogrosidecomposition. As a further example, an anti-glycation composition maycomprise a mineral extract composition, a mogroside/mineral extractcomposition or a mogroside composition in a pharmaceutical formulationfor ocular drops to provide anti-glycation effects to the eye, forexample for diabetics, to treat vision impairment.

Solid or dry anti-glycation compositions comprise a mineral extractcomposition or a mogroside/mineral extract composition or a mogrosidecomposition, and a solid or dry material, such as a food product foringestion by a human or animal. Solids or dry materials include, but arenot limited to, foodstuffs, food products, nutritive and non nutritivesweeteners, pharmaceutical, nutraceutical or dietary supplementformulations. For example, an anti-glycation composition may comprisesolid or dry pharmaceutically acceptable compositions, excipients,fillers or other known pharmaceutical formulations, to be made intodosage units such as tablets, capsules or powders, in combination with amineral extract composition, a mogroside/mineral extract composition ora mogroside composition. The compositions of the present invention mayfunction as additives to foods, and be combined with food products,including foods wherein a dry or liquid a mineral extract composition, amogroside/mineral extract composition or a mogroside composition can beadded, so as to provide anti-glycation activity to the food.

As a specific example, an anti-glycation composition may be added to afood product for human or animal consumption. An anti-glycationsweetener may comprise a mineral extract composition, amogroside/mineral extract composition or a mogroside composition alone,or in combination with a compound or composition that has a sweet taste,or is a recognized sweetening agent. Anti-glycation compositions may beused as a sweetening agent, and may comprise a mineral extractcomposition combined with sweeteners, including but not limited to sweetnatural compounds or compositions such sucrose or maple syrup, orartificial sweeteners. The anti-glycation mineral extract compositionmay be combined with a sweetener, comprising mogroside, to form amogroside/mineral extract composition, an anti-glycation sweetener. Amineral extract composition may be added to a sweetener compound orcomposition, and used for example as a coating in a continuous sprayagglomeration to sugar granules, or added to an alternative naturalsweetener such as erythritol, to provide the sweetener withanti-glycation properties. The mineral extract composition may be addedas a liquid to a stevia extract to provide a combined stevia/mineralextract composition sweetener with anti-glycation properties. A mineralextract composition, a mogroside/mineral extract composition or amogroside composition may be added to sweeteners known to promote AGEsuch as high fructose corn syrup to provide an anti-glycation a mineralextract composition, a mogroside/mineral extract composition or amogroside composition/high fructose corn syrup composition.

Anti-glycation activity, or glycation inhibition activity, are termswhich are used interchangeably, and refer to the ability of a compound,extract or composition to interfere with glycation reactions such thatthe reaction of amino groups of proteins, lipids, or nucleic acids withsugar aldehyde or keto groups to produce modified amino groups, arealtered or prevented or the formation of advanced glycosylationend-products (AGE) are altered or prevented, in vivo or in vitro.

A composition of the present invention comprises natural sweetenercompounds, including but not limited to those derived from Luo Han Guo,which may be used as an anti-glycation sweetener alone or with othercomponents of a composition such as a mineral extract composition taughtherein. Luo Han Guo is a botanical plant also known as MomordicaGrosvenori or Siraitia grosverorii, originally grown in China and nowgrown there and in other places where climate permits. Usually sweetenercompounds, such as those known as mogrosides, are derived from the fruitof the Luo Han Guo plant, though any portion of the plant may beprocessed to yield sweetener compounds. Luo Han Guo fruit is a smallgourd-like fruit having an intensely sweet taste. The fruit contains anaturally occurring compounds called mogrosides, which is thought to bethree hundred times sweeter than cane sugar and is low in calories.Herein, the term mogroside is used to mean one or more, or all of themogroside compounds present in Luo Han Guo fruit, and mogroside is alsoreferred to as Lou Han Guo extract. In literature, the Luo Han Guo plantis also referred to as Lo Han Guo or luohan guo, all of which areintended to refer to the same plant.

Surprisingly, the inventors have found that mogroside has anti-glycationactivity, along with energy promotion and collagen growth stimulation.Methods of the present invention comprise use of a mogroside compositionfor anti-glycation activity, energy promotion and collagen stimulationin compositions for sweetening foods or drinks. Mogroside compositionsin combination with mineral extract compositions such as those taughtherein, are referred to herein as mogroside/mineral extractcompositions. Mogroside compositions comprise a mogroside extract fromLuo Han Guo fruit, and methods for making mogroside or a Luo Han Guofruit extract are known.

An effective amount of a mineral extract composition or amogroside/mineral extract composition or a mogroside composition foranti-glycation activity may or may not be dependent on the type ofsecond component to which a mineral extract composition or amogroside/mineral extract composition or a mogroside composition isadded. An anti-glycation composition may be provided or administered toa subject 1 time a day, two times a day, three times a day or moreoften. An anti-glycation composition may be administered daily, weekly,or monthly in a regular schedule or on an as needed schedule. Ingeneral, an anti-glycation composition may comprise from about 0.0001 gto about 1000 g of the mineral extract, or from about 0.0001 g to about100 g, from about 0.0001 g to about 10 g, from about 0.001 g to about1000 g, from about 0.01 g to about 1000 g, from about 0.1 g to about1000 g, from about 1.0 g to about 100 g, from about 1.0 g to about 10 g,from about 10 g to about 1000 g, and ranges therein between. Forexample, a 12 oz enhanced water beverage may contain 0.1 gram of amineral extract composition, while a 10 oz carbonated beverage with highfructose corn syrup may contain 10 grams of a mineral extractcomposition, and a gallon size maple syrup may contain 300 grams of amineral extract composition.

A mogroside/mineral extract composition may comprise about 0.0001 g toabout 1000 g of the mineral extract, as described above, which is addedto a mogroside composition comprising mogroside in amounts of about0.0001 g to about 1000 g.

A mineral extract composition resulting from the selection of sourcematerial soils and the extraction process are comprised in theanti-glycation compositions that are used in the methods of the presentinvention. Methods of the present invention include methods ofinhibiting formation of glycation end products, inhibition of AGEformation, inhibition of glycation reactions of proteins, lipids and/ornucleic acids, inhibition of aging effects related to glycationreaction, and methods for treatment or prevention of glycation-relatedconditions including, but not limited to, complications of diabetes(Type I and II), rheumatoid arthritis, Alzheimer's disease, uremia,neurotoxicity, atherosclerosis, inflammatory reactions, ventricularhypertrophy, angiopathy, myocarditis, nephritis, arthritis,glomerulonephritis, microangiopathies, and renal insufficiency, ormethods of preventing accumulation of glycation products. Methods forinhibiting glycation or inhibiting AGE formation, prevention ortreatment of glycation-related conditions comprise administering orproviding an effective amount of an anti-glycation compositioncomprising a mineral extract composition or a mogroside/mineral extractcomposition or a mogroside composition, to a human or animal, whereinthe anti-glycation composition alters the effects of glycation,glycation activity, glycation rate or amount of glycation products suchas AGE in the subject. For example, an amount of glycation activity canbe conveniently measured by an A1C test of glycated hemoglobin. Areduction in the A1C measurement indicates a lower amount of glycationactivity in the body. Measurements for glycated proteins are known tothose skilled in the art, see for example U.S. Pat. No. 5,506,144.

Methods of the present invention comprise making and usinganti-glycation compositions. Such compositions may be consumed byhealthy young and adult animals and humans, as well as humans or animalsat risk for developing, or suffering from, diabetes, atherosclerosis orsimilar glycation-related conditions. Food, beverages, and nutritionalsupplement anti-glycation compositions may be used to provideanti-glycation potential to a subject and provide a benefit in loweringthe potential cross-linking of protein and sugars to promote health andwellness. For example, a line of food or beverages having anti-glycationcapability due to the incorporation of a mineral extract composition ofthe present invention may be used by different ages for multiple healthbenefits.

Methods of treatment or prevention of glycation-related conditions orinhibition of glycation levels include providing an effective amount ofan anti-glycation composition comprising a mineral extract compositionor a mogroside/mineral extract composition or a mogroside compositionfor intestinal inflammation. Intestinal inflammation may affect theimmune and nervous systems and contribute to a variety of conditionsincluding food intolerances, allergic reactions, inflammation, cognitivedifficulties, hyperactivity and other behavioral issues. Receptor forAdvanced Glycation Endproducts (RAGE) is a family of cell surfacereceptors associated with inflammatory responses. It is currentlybelieved that RAGE are involved in inflammatory responses in theintestines when consumption of glycation promoting products contact theintestinal and stomach epithelial cell lining. It has been shown thatRAGE are expressed in intestinal epithelial cells, primarilyconcentrated at the lateral membranes close to the apical cell junctioncomplexes. Although RAGE expression is low in epithelium under normalconditions, it is up-regulated during consumption of sugars. Theglycation effect that takes place when eating sugars leads tocrosslinking and inflammation of the intestinal and stomach walls.

In the methods of the present invention for prevention or treatment ofglycation-related conditions, or inhibition of glycation products andAGE, for example, a beverage or foodstuff comprising an anti-glycationcomposition such as a mineral extract composition or a mogroside/mineralextract composition or a mogroside composition may be ingested bysubjects, animals or humans, to reduce the effects of glycation on thelinings of the gastrointestinal system. Such anti-glycation compositionsmay support intestinal anti-glycation effects, enhance intestinaldetoxification of oxidative compounds, promote intestinal nutrientabsorption help retard intestinal inflammatory processes, promote theintestinal role as a gatekeeper of AGEs to the circulatory pathway,encourage intestinal health and help reduce the factors of inflammation,and aid in calming and soothing intestinal glycation-inducedinflammation. Beverages or foodstuff, in addition to comprising ananti-glycation composition, may also comprise botanicals such aschamomile, dandelion, echinecea, milk thistle, gentian, licorice,chickenweed, meadowsweet, goldenseal, spanish black radish, andchlorophyll.

Methods of prevention or treatment of glycation-related conditions, orinhibition of glycation products and AGE, include providing an effectiveamount of an anti-glycation composition comprising a mineral extractcomposition or a mogroside/mineral extract composition or a mogrosidecomposition for cognitive function. Cognition is a general term coveringmany aspects of brain function, including learning, remembering,thinking and reasoning. These processes may decline during the naturalaging process or in the event of degenerative disease. Advancedglycation end products and free radical damage may be a natural part ofaging, leading to reduced cognitive function and motor skills, and maylead to accelerated forms of dementia, Alzheimer's or Parkinson'sdisease. For example, a beverage or foodstuff comprising ananti-glycation composition may be ingested by subjects, animals orhumans, to reduce the effects of glycation on the nervous system, reduceinflammatory reactions, and prevent damage to the circulatory system.Such anti-glycation compositions may be used to protect againstcognitive degradation, restore optimal cognitive functionality,encourage healthy cognitive function, enhance cognitive performance,promote healthy brain function, aid in combating oxidative-inducedcognitive degradation, strengthen cognitive function defense, and tostimulate coherent cognitive processes. Beverages or foodstuff, inaddition to comprising an anti-glycation composition, may also compriseherbal or botanical compounds or extracts of ginko biloba, ginseng,vipocetine, green tea, soy isoflavones, Vitamins E, C, B6, B12,phospholipids (phosphatidylserine and phosphatidylcholine) andcitocoline (a precursor) and glycerophosphocholine, alpha lipoic acid,acetyl-L-carnitine, coenzyme Q 10, creatine, essential fatty acids, DHA,EPA, and resveratrol, or grapeseed extract.

Methods of prevention or treatment of glycation-related conditions, orinhibition of glycation products and AGE, include providing an effectiveamount of an anti-glycation composition comprising a mineral extractcomposition or a mogroside/mineral extract composition or a mogrosidecomposition for vision. A major risk factor in vision loss, cataracts,and macular degeneration is the hardening of the arteries, capillariesand retina in the eyes. It is well established that diabetics suffer amuch higher incidence of vision impairment relative to the generalpopulation, in part as a result of advanced glycation end productaccumulation in the eye. For example, a beverage or foodstuff comprisingan anti-glycation composition may be ingested by subjects, animals orhumans, to reduce the effects of glycation on the eye and associatedstructures. Such compositions are useful for promoting vision wellness,defending against age related vision degradation, restoring eyecapillary circulation, protecting against age related vision impairment,protecting against glycation-induced vision impairment, reducing agerelated vision impairment, promoting health of the eyes, encouraginglens clarity, and sustaining healthy vision. Beverages or foodstuffs, inaddition to comprising an anti-glycation composition, may also compriseherbals such as bilberry, ginkgo biloba, phytonutrients such as lutein,zeaxanthin, lycopene, bioflavonoids, mixed carotenoids, lipoic acid,n-acetylcysteine, and quercetin, amino acids such as taurine,glutathione, cysteine, vitamins, such as Vitamin A, C, E, B-12,betacarotene, essential fatty acids, and other antioxidants (i.e.melatonin)

Methods of prevention or treatment of glycation-related conditions, orinhibition of glycation products and AGE include providing an effectiveamount of an anti-glycation composition comprising a mineral extractcomposition or mogroside/mineral extract composition or mogrosidecomposition for arthritis. Advanced glycation end products (AGEs) arethought to be promoters of inflammation and eventual joint degradationas seen in osteoarthritis and rheumatoid arthritis. It has been shownthat AGEs activate inflammation mediators called MMPs to begin thecascading effect of pain and limited movement flexibility. Synovialfluids become oxidized and subject to glycation-driven hardening.Markers of glycation have been identified as present in elevated amountsin synovial fluids of osteoarthritis and rheumatoid arthritis patientsindicating glycation is a factor in these conditions. Prophylactic useof anti-glycation compositions of the present invention at an early agemay prevent or delay the onset of these conditions and, intake at anyage may reduce the incidence and severity of osteoarthritis andrheumatoid arthritis. Taken at any age, the anti-glycation compositionsof the present invention may limit the cascading damage of glycation andthus reduce the propensity to promote longer term arthritic diseasesthat come with aging.

For example, a beverage or a foodstuff or food product comprising ananti-glycation composition may be ingested by subjects, animals orhumans, to reduce the effects of glycation on the joints or synovialfluid. Such compositions may be used to retard age-related arthriticdegeneration, maintain joint and tendon flexibility, promote healthybone strength and joint elasticity, encourage bone structure integrityand flexibility, defend against glycation-induced joint degradation,promote healthy synovial environment to joints and tendons, encouragemore active lifestyle when living with arthritis, promote longerpreventive wellness for arthritis, and reduce incidence of inflammation,point swelling and tightness.

Beverages or foodstuff, in addition to comprising an anti-glycationcomposition, may also comprise herbals or extracts of herbals such asginger, chinese thunder god vine, willow bark extract, feverfew, cat'sclaw, stinging nettle, boswellia, S-adenosylmethionine (SAMe),chondroitin sulfate, glucosamine, essential fatty acids, and enzymes,such as bromelain, and quercetin.

Methods of prevention or treatment of glycation-related conditions, orinhibition of glycation products and AGE include providing an effectiveamount of an anti-glycation composition comprising a mineral extractcomposition or a mogroside/mineral extract composition or a mogrosidecomposition for erectile dysfunction (ED). Glycation has been proposedto play a role in age-related processes by forming protein and DNAadducts and cross-links. These cross-links may contribute to erectiledysfunction by scavenging nitric oxide, which is needed for erection.Additionally, glycation causes hardening of arteries which inhibits thearterial flexibility required to maintain an erection. AGE have beendemonstrated to impair erectile function by affecting the functionalcapabilities of the corpus cavemosum and by interfering with theproduction of natural penile vasodilating agents, endothelial andneuronal nitric oxide (NO). For example, a beverage or foodstuffcomprising an anti-glycation composition may be ingested by subjects,animals or humans, to reduce the effects of glycation on the ability toacquire and maintain an erection. Such compositions may be used topromote healthy sexual function, retard age related ED circulatorydegradation, prevent glycation-induced ED, to maximize sexualcirculation processes, enhance healthy erectile performance, andencourage normal erectile performance. Beverages or foodstuff, inaddition to comprising an anti-glycation composition, may also compriseVitamin C & E, bioflavonoids, essential fatty acids, yohimbe bark, hornygoat weed, maca, saw palmetto, and man bao.

Anti-glycation compositions for these and other glycation-relatedconditions may comprise ready-to-eat-cereals, fruit juices, candy bars,chewing gum, nutritional supplements, enhanced water beverages,carbonated and non-carbonated drinks, alcoholic beverages such as beerand wine, baby food, and many other foodstuffs and beverages. Theanti-glycation compositions of the present invention may be used ananimal feed additive.

AGEs are thought to play a role in decreasing cellular metabolic rateand function. The anti-glycation mineral extract composition of thepresent invention may play a role in retarding the decrease in metabolicrate due to glycation endproducts. In addition, the anti-glycationcompositions of the present invention may also provide energy to thecells of the body by enhancing mitochondrial function. See examplesherein where the compositions taught herein are effective inmitochondrial metabolism. For example, a beverage or foodstuffcomprising an anti-glycation composition comprising the mineral extractcomposition or a mogroside/mineral extract composition or a mogrosidecomposition may be ingested by subjects, animals or humans, to enhanceenergy metabolism in the body. Such compositions provide chemicalstimulant-free metabolic enhancement.

AGEs are thought to play a role in degrading collagen. Theanti-glycation compositions of the present invention may play a role inretarding collagen degradation due to glycation endproducts. Methods ofprevention or treatment of glycation-related conditions, or inhibitionof glycation products and AGE include providing an effective amount ofan anti-glycation composition comprising a mineral extract compositionor a mogroside/mineral extract composition or a mogroside compositionfor collagen production and maintenance. Collagen is a family of highlycharacteristic, fibrous proteins constituting 25 percent of totalprotein mass in human body. With aging, collagen production decreasesand collagen degeneration increase. Whether to promote younger skin, forhealthier bones and tendons, collagen stimulation is a desirableattribute for an ingredient in food and beverages. Examples ofstimulation of type I collagen to nearly 90% above the non-treated(water) control is shown herein. MMPs, matrix metalloproteinases, areproteolytic enzymes or proteases that digest or breakdown proteins inthe body. Over 30 different types of MMPs have been discovered to datefor multiple enzymatic digestive functions and inflammation mediation.On skin, the primary role of MMP enzymes is to maintain a steady stateof recycling the skin matrix, particularly the structural proteinscollagen and some are part of the inflammation pathway. As part ofaging, MMPs tend to over-express themselves. In addition, inflammation,irritation, and environmental stress (free radicals) elevate the levelsof MMP in the skin to create greater digestion of collagen. In vitrostudies taught herein using human fibroblast indicate a mineral extractcomposition of the present invention efficiently blockscollagen-digesting enzymes at concentrations levels as low as 0.005%. Atconcentration levels of 0.05%, a 100% inhibitory effect on MMP was seen.

AGEs are oxidative promoters of free radicals. Anti-glycationcompositions of the present invention may play a role in combating freeradicals that are generated by glycation endproducts. Methods of thepresent invention comprise treatment or inhibition of oxidationcomprising providing an effective amount of an antioxidant compositioncomprising a mineral extract composition or a mogroside/mineral extractcomposition or a mogroside composition described herein in combinationwith a second component such as a foodstuff or beverage. There are manyenvironmental and lifestyle factors which increase the level ofoxidation in living cells to unhealthy levels, all which accelerate theaging process and create potential for disease. Because of its damagingeffect on vital biological systems, oxidative stress has been implicatedin more than 100 diseases and in aging. Antioxidants are intimatelyinvolved in the prevention of cellular damage—the common pathway forcancer, aging, and a variety of other diseases. Endurance exercises canincrease oxygen utilization from 10 to 20 times over the resting state.This greatly increases the generation of free radicals, promptingconcern about enhanced damage to muscles and other tissues. Beverages orfoodstuff, in addition to comprising an antioxidant compositioncomprising a mineral extract composition or a mogroside/mineral extractcomposition or a mogroside composition of the present invention, mayalso comprise vitamins A, C and E, and plant polyphenols.

Though not wishing to be bound by any particular theory, it is currentlybelieved that skin aging is accelerated by AGEs and their effects ondegradation of HA and collagen, free radicals and inflammation. Themineral extract compositions or mogroside/mineral extract compositionsor mogroside compositions disclosed herein may increase theconcentrations of hyaluronic acid (HA) as demonstrated in the followingexample. This could additionally aid in the synovial fluid environment.Ability to increase HA was assessed with adult human dermal fibroblastsplated in high glucose DMEM supplemented with 5% serum at 10,000 cellsper well and a mineral extract composition was added. After 5 days, cellculture conditioned media were collected and samples of 100 ul per testcondition were used in the HA assay. HA assay was performed usingHyaluronan Enzyme-Linked immunosorbent Assay Kit (HA-ELISA, cat. #K-1200) from Echelon (Salt Lake City, Utah). The mineral extractcomposition was observed to produce >20% HA stimulation. Coupled withthe anti-glycation, collagen stimulation and protection,anti-inflammatory and antioxidant properties, methods of prevention ortreatment of glycation-related conditions, or inhibition of glycationproducts and AGE, include providing an effective amount of ananti-glycation composition comprising a mineral extract composition or amogroside/mineral extract composition or a mogroside composition fortopical cosmetic treatments or orally administered beautificationproducts, such as beverages and foodstuff for treatment of skinanti-aging. Since, advanced glycation end products (AGEs) have beenestablished as promoters of inflammation, inflammation has beenestablished as a promoter of skin aging.

In general, the present invention comprises anti-glycation compositionsand methods of making and using anti-glycation compositions, and methodsfor treating and preventing glycation-related conditions. A method oftreating or preventing glycation-related conditions, comprisesadministering to a human or animal an effective amount of ananti-glycation composition comprising a mineral extract composition or amogroside/mineral extract composition or a mogroside composition,wherein the amount is effective in reducing at least a portion of theglycation events in a human or animal. An anti-glycation composition maycomprise a mineral extract composition, an anti-glycation compositionmay comprise a mogroside/mineral extract composition, or ananti-glycation composition may comprise a mogroside composition. Ananti-glycation composition may further comprise a foodstuff or abeverage. Glycation-related conditions comprise formation of glycationend products, AGE formation, glycation reactions of proteins, lipidsand/or nucleic acids, aging effects related to glycation reactions, andcomplications of diabetes (Type I and II), rheumatoid arthritis,Alzheimer's disease, uremia, neurotoxicity, atherosclerosis,inflammatory reactions, ventricular hypertrophy, angiopathy,myocarditis, nephritis, arthritis, glomerulonephritis,microangiopathies, and renal insufficiency, or accumulation of glycationproducts.

An anti-glycation composition may comprise a mogroside and a mineralextract composition in combination, and may be further combined with afoodstuff or a beverage. An anti-glycation composition may comprise amogroside and a mineral extract composition in combination, and may befurther combined with a sweetener composition.

A method of inhibiting glycation reactions comprises providing aneffective amount of an anti-glycation composition comprising a mineralextract composition or a mogroside/mineral extract composition or amogroside composition, and inhibiting a glycation reaction. The methodmay comprise an anti-glycation composition comprising a mineral extractcomposition, an anti-glycation composition comprising amogroside/mineral extract composition, or an anti-glycation compositioncomprising a mogroside composition. The method may further comprise ananti-glycation composition comprising a foodstuff or a beverage. Themethod may comprise providing an anti-glycation composition in vivo to ahuman or animal or may be provided in vitro.

DEFINITIONS USED HEREIN

Chemical element. Any of more than 100 fundamental metallic andnonmetallic substances that consist of atoms of only one kind and thateither singly or in combination constitute all matter, most of thesesubstances lighter in weight than and including uranium being found innature and the rest being produced artificially by causing changes inthe atom nucleus.

Clay. A natural or synthetic colloidal lusterless earthy compositionthat includes tiny sheet-like layered particles of alumina and/or silicathat are less than about 0.002 millimeters in size, that is generallyplastic when moist, and that, when naturally occurring, includesdecomposed igneous and/or metamorphic rocks. Most clays have a pH in therange of about 4.5 to 8.5. Natural and synthetic clays include mineralelements. Clays can, in additional to having particles less than fivemicrons in size, include particles having a size greater than fivemicrons.

Leonardite. A soft, loose-textured coal that has low BTU value.Leonardite is a humate, can include up to 70% by weight minerals, can beformed from lignite, can occur naturally as the result of not beingheated and pressurized over time to the extent necessary to produceanthracite, lignite, or bituminous coal, and, can include compost as acomponent.

Mineral. Any naturally occurring chemical element or compound. A mineralhas a characteristic crystal structure and chemical composition or rangeof compositions.

Mineral element. A chemical element that occurs naturally as or in amineral. A mineral element may be produced using synthetic ormanufacturing processes, however, each mineral element does occurnaturally as or in a mineral.

Rare earth or rare earth element. Any one of a group of metallicelements with atomic numbers 58 through 71, including cerium,praseodymium, neodymium, promethium, samarium, euroopium, gadolinium,terbium, dysprosium, holmium, erbium, thulium, ytterbium, and lutetium.In nature, rare earth elements are bound in combination with nonmetallicelements in the form of phosphates, carbonates, fluorides, silicates,and tantalates.

Sand. A loose material consisting of small but easily distinguishablegrains usually less than two millimeters in diameter and more than about0.02 millimeters in diameter, most commonly of quartz, resulting fromthe disintegration of rocks.

Silt. Unconsolidated or loose sedimentary material whose constituentrock particles are finer than grains of sand and larger than clayparticles, specifically, material consisting of mineral soil particlesranging in diameter from about 0.02 to 0.002 millimeters.

It must be noted that, as used in this specification and the appendedclaims, the singular forms “a,” “an,” and “the” include plural referentsunless the context clearly dictates otherwise.

All patents, patent applications and references included herein arespecifically incorporated by reference in their entireties.

It should be understood, of course, that the foregoing relates only topreferred embodiments of the present invention and that numerousmodifications or alterations may be made therein without departing fromthe spirit and the scope of the invention as set forth in thisdisclosure.

The present invention is further illustrated by the following examples,which are not to be construed in any way as imposing limitations uponthe scope thereof. On the contrary, it is to be clearly understood thatresort may be had to various other embodiments, modifications, andequivalents thereof which, after reading the description herein, maysuggest themselves to those skilled in the art without departing fromthe spirit of the present invention and/or the scope of the appendedclaims.

EXAMPLES Example 1

Three mineral extract compositions were evaluated to test theanti-glycation effect.

Each reaction mixture contained 10 mg/ml albumin (Sigma) in PBS with 500mM glucose (Sigma G8270) in PBS. The negative control was 10 mg/mlalbumin without glucose. A negative control was used for eachexperimental point. The positive control was 10 mg/ml albumin with 500mM glucose with 1 mM aminoguanidine hydrochloride (Sigma 396494).

Sample Preparation

Each mineral extract composition was diluted in type I sterile water to10 mg/ml, sterilized by 0.22 micron filtration and incubated atdilutions 100 ug/ml, 10 ug/ml, 1 ug/ml and 0.1 ug/ml with the reactionmixture with or without glucose for 11 days at 37° C. in the presence ofsodium azide.

Protein glycation was detected by the increase of non-tryptophanfluorescence (excitation at 360 nm, emission at 460 nm) using microplatefluorometer Cytofluor 2350 (Millipore), as described (Argirova andArgirov, 2003). The glycation value for each experimental point wasobtained by subtracting the background reading (samples withoutglucose).

Results and Discussion

As seen in FIG. 1, 0 is the negative control, and each mineral extractcomposition showed inhibition of albumin glycation at 50 ug/ml, with # 1showing the overall best inhibitory activity. Aminoguanidine (AG) (1 mM)had good inhibitory activity, which is its known activity.

Example 2 Anti-Glycation Activity

Normal human dermal fibroblasts (NHDF) were cultivated in conditionsthat allow the synthesis of high amounts of extracellular matrix (ECM).NHDF were grown to confluence in normal medium in adequate format.Vitamin C was added to the media to induce matrix synthesis/deposition

Cells were treated, (or not treated for the negative control) by threeconcentrations of the mineral extract composition or by a referencecompound for a positive control (aminoguanidine). All the conditionswere performed in triplicate.

An excess of glucose was added to the cells and the cells were incubatedat 37° C. for 15 days. At the end of the time, ECM proteins (mainlycollagen) were extracted and purified and a fraction of each sample wasloaded onto nitrocellulose in reproducible spots.

The introduction of AGEs in collagen was shown using an anti-AGEantibody and it was labeled using a peroxidase conjugate andchemiluminescent reaction (ECL). Relative signal qualification wasperformed using a chemiluminescense imager.

The results are illustrated below in Tables 1 and 2.

TABLE 1 First membrane Intensity % Treatment Conc. (AU) Average SemControl Control — 49908 53561 1843 100 54965 55809 Aminoguanidine 1mg/ml 24719 33454 4377 62 38328 37316 Mineral Extract 0.1 μg/ml 4627042886 2991 80 Composition 1 45465 36922 25 μg/ml 48675 51128 6560 9563517 41193 250 μg/ml 38893 44343 2755 83 47772 46363 Mineral Extract0.1 μg/ml 48856 48340 1823 90 Composition 2 51209 44956 25 μg/ml 5123344177 3658 82 38977 42322 250 μg/ml 43883 40454 3144 76 43304 34176Mineral Extract 0.1 μg/ml 40338 45520 3833 85 Composition 3 53004 4321925 μg/ml 46324 45936 1593 86 48480 43003 250 μg/ml 37197 41239 2569 7746008 40513 Mineral Extract 0.1 μg/ml 34161 42089 4034 79 Composition 447349 44758 25 μg/ml 43224 50402 7095 94 64592 43389 250 μg/ml 4493042543 4084 79 48115 34585 sem: standard error of the mean AU: arbituaryunit

TABLE 2 Membrane 2 Intensity % Treatment Conc. (AU) Average Sem ControlControl — 53903 60294 4067 100 59133 67846 Aminoguanidine 1 mg/ml 3646038752 1414 64 38464 41333 Control — 53903 60294 4067 100 59133 67846Aminoguanidine 1 mg/ml 36460 38752 1414 64 38464 41333 Mineral Extract0.1 μg/ml 38940 45072 3066 75 Composition 5 48090 48186 25 μg/ml 5230656723 2224 94 58468 59394 250 μg/ml 50460 51318 439 85 51585 51908Mineral Extract 50 μg/ml 40393 46127 3053 77 Composition 6 47176 50811200 μg/ml 36099 45666 5859 76 44590 56308 500 μg/ml 44656 50828 3314 8451825 56004 sem: standard error of the mean AU: arbituary unit

The mineral extract compositions showed a tendency to decrease theproduction of the end product of glycation (AGE).

Example 3

The objective of this assay was to test the effect of mineral extractcompositions (6 lots) on the mitochondrial metabolism in a cell culturepopulation, using MTT assay. MTT assay measures the activity ofsuccinate dehydrogenase, a key enzyme in the respiratory electrontransport chain in mitochondria (Berridge & Tan, 1993).

Methods

Mineral extract compositions were diluted in type I sterile water to 10mg/ml, sterilized by 0.22 micron filtration and incubated at dilutions500 ug/ml, 50 ug/ml and 5 ug/ml and 0.5 ug/ml with 2,500 human dermalfibroblasts from an 81 year old female donor (Cascade Biologics, lot#061215-901) per well for 72 h in high glucose DMEM medium with 2.5% calfserum.

For mitochondrial metabolism measurement, at the end of the experiment,MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Sigmacat. # M 5655) was added to cell cultures and incubated for 2 h. Culturemedia were then discarded and intracellular MTT reduction productformazan was solubilized in 100% DMSO. The colorimetric signalproportional to the mitochondrial activity in the cell cultures wasmeasured with the BioRad microplate spectrophotometer 3550-UV at 570 nm.

For cell number measurement, at the end of the experiment, cytoskeletalproteins were stained with sulforhodamine B and the colorimetric signalproportional to cell numbers measured with the BioRad microplatespectrophotometer 3550-UV at 570 nm.

The mitochondrial metabolism was standardized with regard to cellnumbers by establishing the ratio of the two corresponding signals.

Results and Discussion

See FIGS. 2 A and B for results. All mineral extract compositions lotstested exhibited similar pattern, with one (#2) stimulatingmitochondrial metabolism up to nearly 100% over the baseline. See FIG.2A. 0 is the negative control where water was added to the cells, andeach of six samples of mineral extract composition, labeled 1-6, in 500ug/ml, 50 ug/ml and 5 ug/ml and 0.5 ug/ml concentration for each of the6 samples. C is creatine, added to the cells at 500 ug/ml.

Interestingly, the dermal fibroblasts from an elderly donor were onlymarginally sensitive to creatine (6.3% stimulation), and were notsensitive to basic fibroblast growth factor (bFGF, results not shown).Furthermore, importantly, mineral extract compositions did not stimulatecell proliferation in the assay, just the metabolism. See FIG. 2B.

Example 4

Collagen secreted by dermal fibroblasts is a major component of theextracellular matrix in the skin. In aged and photodamaged skin, the newcollagen pool is decreased due to the inferior amount and quality ofdermal fibroblasts. The object of this project was to test the mineralextract composition on type I collagen levels in human dermal fibroblastconditioned medium.

Methods

Normal human dermal fibroblasts (passage 7, lot# 7F1254, Cambrex,Walkersville, Md.) were seeded in a 96-well plate (plate # 431) in DMEMmedium (high glucose) containing 5% fetal calf serum, and grown to latesubconfluent stage. Aqueous solutions of mineral extract compositionwere prepared in sterile Type I water and added to cell cultures at 1/20dilution. Water was the non-treated control and magnesium ascorbylphosphate (MAP cat. # A8960, Sigma, St. Louis, Mo.) was the positivecontrol. Cell culture conditioned media were harvested 5 days after thestart of the experiment and tested for type I collagen by sandwich ELISAusing affinity-purified antibodies, followed by streptavidin-avidin-HRPconjugate and ABTS, according to standard ELISA protocol (Dobak et al.,1994, Zhao et al, 2005). The calorimetric signal proportional tocollagen content was measured with the BioRad microplatespectrophotometer 3550-UV at 405 nm. See FIG. 3, Effect of mineralextract composition on type I collagen in HDF-conditioned medium.

Results and Discussion

Strong stimulation of collagen I was seen for the positive control(MAP), See FIG. 3. The mineral extract composition showed an excellent,bell-shape stimulation of type I collagen up to nearly 90% above thenon-treated (water) control, comparable with the positive control (MAP).The bell shape of the dose-response curve may indicate that the optimalconcentration of the mineral extract composition for type I collagenstimulation is between 0.01 and 0.1 mg/ml (0.1-1%).

Example 5

Metalloproteinase (MP) (collagenase) activity was measured with Enzcheckkit from Molecular Probes (Invitrogen, IL) using quenched fluorescentgelatin and Clostridium collagenase IV, a generic metalloproteinase.Mineral extract composition, in dilutions of 500 ug/ml, 50 ug/ml and 5ug/ml and 0.5 ug/ml, were incubated in the presence of collagenasesubstrate-quenched fluorescin-linked gelatin and in the presence of theproteolytic enzyme collagenase. Phenanthroline, a potent MP inhibitorwas used as positive control at 100 ug/ml. The kinetics of the releaseof the digested, fluorescent gelatin were measured atexcitation/emission wavelengths of 485/530 nm with Millipore Cytofluor2350 microfluorometer.

Results and Discussion

As illustrated in FIG. 4, the mineral extract composition hasmetalloproteinase-inhibitory activity. This activity can be detected atconcentrations as low as 50 ug/ml (6% inhibition) and it is 100% at 500ug/ml. As expected, MP activity was totally inhibited by phenanthroline.

Most metalloproteinase inhibitors are indiscriminate bivalent cationchelators. The mineral extract composition may act through a differentmechanism of action. It is worth investigation whether this potentiallynovel mechanism of action impairs specificity for a subset ofmetalloproteinases, which would be of interest for dermatologicalapplications.

Example 6

The mineral extract composition was tested for its antioxidant effect inan independent in vitro study to assess the Oxygen Radical AbsorbanceCapacity (ORAC Score), using a standard fluorescent assay technique.

The leading antioxidant fruits have been reported to have ORAC scores inthe range of 15-30, which is quite significant antioxidant capacity. Themineral extract composition samples, tested using the same protocol, wasfound to have between 10-30 times greater ORAC scores than the leadingantioxidant fruits on an equivalent weight basis.

ORAC Value of Fruits (μmole TE/g) Cherry 15 Strawberry 24 Raspberry 28Blackberry 28 Blueberry 28 Pomegranate 32

Oxygen Radical Absorbance Capacity of Mineral Extract Composition

Because of its damaging effect on vital biological systems, oxidativestress has been implicated in more than 100 diseases and aging (Ames etal., 1993). The objective of this test was to measure the antioxidantpotential of several samples of mineral extract composition using oxygenradical absorbance capacity (ORAC) assay.

Methods

ORAC assay was performed according to the method described by Ou et al.(2001), with minor modifications (Sunny BioDiscovery Protocol# 21). TheORAC assay measures the ability of antioxidant components to inhibit thedecline in disodium fluorescein (FL) (Sigma-Aldrich, St Louis, Mo.)fluorescence that is induced by the peroxyl radical generator,2′,2′-Azobis(2-amidinopropane) dihydrochloride (AAPH) (Wako Chemicals,Richmond, Va.).

Samples of mineral extract compositions were diluted in type I sterilewater to 10 mg/ml, sterilized by 0.22 micron filtration and added at 10ug/ml to reaction mixtures. Trolox (freshly prepared in type I water) atconcentrations 1 ug/ml, 5 ug/ml and 10 ug/ml was used for the generationof standard curve, by plotting the Area Under the Curve (AUC) calculatedwith the NIH ImageJ software, against Trolox concentrations expressed inmicromoles/liter. AUC for each sample was then applied to the Troloxstandard curve. See Table 3.

TABLE 3 ORAC Values Mineral Extract Composition Antioxidant Activity(sample no.) (umoles TE/g) 1 1000 2 925 3 1400 4 925

Example 7 An Anti-Glycation Composition

An anti-glycation composition comprising

Fresh Orange Juice 98.80% (weight percent)

Potassium Sorbate 0.15%

Vitamin E (Tocopherol) 0.05%

Dry Mineral Extract Composition of Table 11.00%

Procedure:

1. Using suitable press equipment, squeeze orange juice

2. Add and mix in Potassium Sorbate and Tocopherol

3. Add and mix Mineral Extract Composition

4. Pack and chill at 5-8 .degree. C.

Mineral content of one liter of Processed Orange Juice delivers no lessthan one ppm of Macro Minerals consisting of a blend of Calcium,Chlorine, Magnesium, Manganese, Phosphorous, Potassium, Silicon, Sodium,and no less that 0.0001 ppm of Micro Minerals consisting of a blend ofAluminum, Antimony, Arsenic, Barium, Beryllium, Bismuth, Boron, Bromine,Cadmium, Cerium, Cesium, Chromium, Cobalt, Copper, Dysprosium, Erbium,Europium, Fluorine, Gadolinium, Gold, Hafnium, Holmium, Iodine, Indium,Iridium, Iron, Lanthanum, Lead, Lithium, Lutetium, Mercury, Molybdenum,Neodymium, Nickel, Niobium, Palladium, Platinum, Praseodymium, Rhenium,Rhodium, Rubidium, Ruthenium, Samarium, Scandium, Selenium, Silver,Strontium, Sulfur, Tantalum, Terbium, Tellurium, Thallium, Thorium,Thulium, Tin, Titanium, Tungsten, Vanadium, Ytterbium, Yttrium, Zinc,Zirconium.

Example 8 Beverage Additive—Powdered Concentrate Mineral Pack

Package 7 g of the dry mineral extract composition of Table I in foilpack. Mixing the 7 g of dry mineral extract composition in the foil packinto 12 ounces of any beverage including water delivers no less than oneppm of Macro Minerals consisting of a blend of Calcium, Chlorine,Magnesium, Manganese, Phosphorous, Potassium, Silicon, Sodium, and noless that 0.0001 ppm of Micro Minerals consisting of a blend ofAluminum, Antimony, Arsenic, Barium, Beryllium, Bismuth, Boron, Bromine,Cadmium, Cerium, Cesium, Chromium, Cobalt, Copper, Dysprosium, Erbium,Europium, Fluorine, Gadolinium, Gold, Hafnium, Holmium, Iodine, Indium,Iridium, Iron, Lanthanum, Lead, Lithium, Lutetium, Mercury, Molybdenum,Neodymium, Nickel, Niobium, Palladium, Platinum, Praseodymium, Rhenium,Rhodium, Rubidium, Ruthenium, Samarium, Scandium, Selenium, Silver,Strontium, Sulfur, Tantalum, Terbium, Tellurium, Thallium, Thorium,Thulium, Tin, Titanium, Tungsten, Vanadium, Ytterbium, Yttrium, Zinc,Zirconium.

Example 9 Effect of a Mogroside/mineral extract Composition and itsComponents on Type 1 Collagen

A mogroside/mineral extract composition is made by combining a 3% liquidmineral extract composition at about 84% w/w % with citric acid (0.01%w/w %) and preservatives (at least 0.01% w/w %) and di- and tripeptidesfrom casein hydrolysate (1.0% w/w %). This mixture is combined withsoluble dietary fiber (1.50% w/w %) and modified food starch (1.60% w/w%). This mixture is mixed with sorbitol solution, 70% USP/FCC (9.0% w/w%) and powdered mogrosides (luo han guo fruit extract) (MB NorthAmerica) (3.0% w/w %). This mixture is combined with Flavor, (0.5% w/w%). Referred to herein as SS II.

Collagen is the main component of connective tissue (fascia), cartilage,ligaments, tendons, bone and teeth and it also provides structuralsupport to blood vessels. The objective of this assay was to determinethe effect of a mogroside/mineral extract composition and its individualcomponents on type 1 collagen levels in human dermal fibroblastconditioned medium.

Methods

A mineral extract composition (TL), Lot# 100-151106, 3% Solution, and amogroside/mineral extract composition as taught herein (SS II),mogrosides of Luo Han Guo Extract (Luo HG, Lot # MOG01-060502),Erythritol (Eryt, Lot # 07241BP952) and Xylitol (Xylit, Lot # H125T7G1)were tested in the assay. All test materials were kept at roomtemperature. Materials were diluted in type 1 sterile water, filteredthrough a 0.22μ filter and assayed at final concentrations 1%, 0.5%,0.1% 0.05% and 0.01% (v:v) for TL and SS II, and 0.5%, 0.1%, 0.05% and0.01% (w:v) for Luo HG, Eryt and Xylit, on adult human dermalfibroblasts (aHDF, donor 58 years of age, Lonza, lot# 7F39=019 breast)in high glucose DMEM with 5% calf serum. Water was the non-treatedcontrol and magnesium ascorbyl phosphate (MAP cat. # A8960, Sigma, St.Louis, Mo.) was the positive control. Cell culture conditioned mediawere harvested 72 h after the start of the experiment and tested fortype 1 collagen by sandwich ELISA using affinity-purified antibodies,followed by streptavidin-avidin-HRP conjugate and ABTS, according tostandard ELISA protocol (Dobak et al., 1994, Zhao et al, 2005). Thecolorimetric signal proportional to collagen content was measured withthe BioRad microplate spectrophotometer 3550-UV at 405 nm.

Results and Discussion

As illustrated in FIG. 5, TL and SS II had a strong dose-dependantcollagen-stimulatory activity at 1% and 0.5% (up to 54% for TL and 49%for SS II). Luo HG had a powerful, dose-dependant stimulatory activityat 0.1% and 0.05% up to 77%). In contrast, Erythritol and Xylitol had nosignificant activity at all concentrations tested. 0 is water, thenon-treated control, MAP was used at 50 μg/mL, Luo HG is indicated by Lin FIG. 5.

Example 10 Effect of a Mogroside/mineral extract Composition, a MineralExtract Composition, Sucralose and Erythritol on MitochondrialMetabolism

The objective of this Example was to test the effect of 4 samples: Amogroside/mineral extract composition (Labeled—1 in FIG. 6A), mineralextract composition (Labeled—2 in FIG. 6A), Sucralose liquid concentrate(Labeled—3 in FIG. 6A) and erythritol (Labeled—4 in FIG. 6A) on themitochondrial metabolism I fibroblast populations, using MTT assay. MTTassay measures the activity of succinate dehydrogenase, a key enzyme inthe respiratory electron transport chain in mitrochondria (Berridge &Tan, 1993).

Methods

Test materials were mogroside/mineral extract composition as made abovein Example 9, mineral extract composition (˜3% Solution), SucraloseLiquid Concentrate (25% Sucralose by weight)—lot # F2304B311LB andErythritol (25% Aqueous Solution)—lot # RFA 2104-35, and were kept atroom temperature. Materials were diluted in type 1 sterile water,filtered through a 0.22μ filter and assayed at final concentrations of2.5%, 0.5% and 0.05% (v:v) on human dermal fibroblasts (Invitrogen) for72 h in high glucose DMEM medium with 5% calf serum.

In order to measure mitochondrial metabolism in whole cell populations,at the end of the experiment, MTT(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Sigmacat. # M 5655) was added to cell cultures and incubation was continuedfor an additional 2 hours. Culture media were then discarded andintracellular MTT reduction product formazan was solubilized in 90%isopropanol. The colorimetric signal proportional to the mitochondrialactivity in the cell cultures was measured with the BioRad microplatespectrophotometer 3550-UV at 570 nm.

Results and Discussion

The results show that the mogroside/mineral extract composition hasmetabolism-stimulatory activity. The mineral extract composition had adose-response activity, while Sucralose inhibited cell metabolism andErythritol had no activity at tested concentrations (see FIG. 6A). Theresults of this first experiment (performed in quadruplicate) werefurther confirmed and reproduced by the repetition of one dose of eachtest material (see FIG. 6B). Basic Fibroblast Growth Factor (FGF at 15nM) was used as positive control and showed metabolic stimulation, asexpected. 0 represents the water, non-treated sample.

Example 11 Effect of a Mogroside/Mineral Extract Composition and itsComponents on Protein Glycation

The Maillard Reaction (non enzymatic glycation) is a chain of reactionsresulting in crosslinkage of amine groups on macromolecules such asextracellular matrix proteins in the skin with carbonyl groups onreducing sugars. These crosslinked macromolecules are called AdvancedGlycation End products (AGEs). The formation of AGEs is enhanced by freeradicals. It is a marker of physiopathologies such as diabetes andatherosclerosis, and is associated with aging and photoaging processes(van Boekel et al., 1991). The objective of this assay was to determinethe effect of a mogroside/mineral extract composition and its individualcomponents on AGE formation in the albumin/glucose model system.

Methods

Mineral extract composition (TL, ˜3% Solution) and a mogroside/mineralextract composition (SS II), Luo Han Guo Extract (L, Lot #MOG01-060502), Erythritol (E, Lot # 07J241BP952) and Xylitol (X, Lot #H125T7G1) were kept at room temperature. Materials were diluted in type1 sterile water, filtered through a 0.22μ filter and assayed at finalconcentration of 1%, (v:v) for TL and SS II, and 0.5%, 0.1% 0.05% and0.01% (w:v) for L, E and X, for three weeks days at 37° C. in thepresence or absence of glucose (Sigma G8270), in the medium containing10 mg/ml of albumin and sodium azide. The positive inhibitor control wasaminoguanindine hydrochloride (AG) at 1 mM, (Sigma 396494).

Protein glycation was detected by the increase of non-tryptophanfluorescence (excitation at 360 nm, emission at 460 nm) using microplatefluorometer Cytofluor 2350 (Millipore), as previously described(Argirova and Argirov, 2003). The glycation value for each experimentalpoint was obtained by subtracting the background reading (sampleswithout glucose) and was expressed as % of control (water).

Results and Discussion

The results show that the mineral extract composition and themogroside/mineral extract composition have a moderate (20-25%) glycationinhibitory activity at 1% concentration and no inhibitory activity atall other concentrations tested. Luo Han Guo extract showed adose-dependant glycation-inhibitory effect at all concentrations tested(up to nearly 90% inhibition at 0.5%) in this model system. Xylitol hadno effect and Erythritol had a moderate inhibitory effect at lowerconcentrations.

Aminoguanidine (AG) showed a strong glycation-inhibitory activitydemonstrating the technical success of the experiment. See FIG. 7.

Example 12

The objective of this experiment was to determine the effect of amineral extract composition at 0.5% (v:v) on the gene expression patternin human adult fibroblasts.

Methods

Human fibroblasts (lot#7F3019, breast, donor 58 years of age) wereobtained from Lonza, Inc. and cultured according to the manufacturer'sinstructions. mineral extract composition (Lot# 100-151106) was added toconfluent, established cell cultures at 0.5% (v:v) in DMEM (highglucose)/5% FCS for 48 h, in 75 cm2 flasks. Upon completion of theincubation, cells were trypsinized, pelleted, and snap frozen in liquidnitrogen. The pellets contained about 4 millions cells.

Cells were then subjected to RNA extraction with Qiagen kit. The qualityof extracted RNA was assayed twice by electrophoresis (after extractionand before microarray analysis). Samples were hybridized in technicalduplicates using human OneArray platform from Phalanx Biotech (PaloAlto, Calif.). The Excel file yielding information on over 30,000 probeswas then further processed in-house to eliminate differences with high pvalues (p>0.1) and low fold change (<2). All genes described as“uncategorized” and “putative” were excluded from the final analysis.Array Studio V2.5 (Omicsoft) software was used to identify functionalcategories affected by the test materials.

Results and Discussion

The quantity and quality of isolated RNA was excellent as was the ratioof nucleic acids to proteins, indicating that RNA was not only intactbut also free of proteinaceous contaminants. The microarrayhybridization was successful. Treatment with the mineral extractcomposition showed variation in gene expression pattern. The mineralextract composition modulated the expression of 2914 probes, whichrepresents about 9% of the total probes. The Array Studio analysisshowed that the mineral extract composition significantly modulated 20functional categories of genes.

The cellular metabolism category was the most significantly modulated.For example, a consistent upregulation of precursors of mitochondrialribosomal proteins and NADH dehydrogenases was seen, suggestingactivation of mitochondrial metabolism through the upregulation of thesynthesis of effectors implicated in the generation of ATP. Furtherindication of increased mitochondrial activity is the upregulation ofcytochrome c oxidase—the terminal enzyme of the mitochondrialrespiratory chain, which plays a key role in the regulation of aerobicproduction of energy.

Another significantly modulated category was the one involved insphingolipid metabolic process. An over 5 fold increase in theexpression of MD-1 protein was seen. This gene/protein is involved inthe synthesis of glycan glycosphingolipids, molecules that are involvedwith the integrity of cell membranes. Compounds benefiting this pathwaymay be useful for skin care applications. Other genes that wereupregulated include those involved in detoxification/antioxidantactivity (over 2 times stimulation of Peroxiredoxin-5 and SuperoxideDismutase—SOD—expression), inhibition of cell death (through caspasepathway inhibition) and upregulation of hyaluronic acid and type Icollagen synthesis.

Example 13 A Dry Sweetener Composition

This composition is an example of sweetener comprising a mineral extractcomposition, Luo Han Guo Extract of mogrosides, and other ingredients toform a sweetener. See the Table below for specific amounts.

INGREDIENTS C.T.F.A.NAME W/W % Phase A. Phase A. Phase A. 1-MineralExtract Powder 1-Mineral Extract Powder 6.00 2-Citric Acid, Anhydrous,2-Citric Acid, Anhydrous, 0.20 USP, FCC USP, FCC 3-Sodium Benzoate, NF,3-Sodium Benzoate, NF, 0.20 FCC FCC 4-Potassium Sorbate, NF, 4-PotassiumSorbate, NF, 0.20 FCC FCC 5-Nutriose FM 06 5-Dextrin (Soluble Dietary3.50 Fiber) 6-N-Zorbit M 6-Tapioca Maltodextrin 52.90 7-Sorbogem 7127-Sorbitol, NF/FCC 10.50 Crystalline Sorbitol NF/FCC 8-Luo Han Guo Fruit8-Momordica Grosvenori 5.00 Concentrate Swingle Mogrosides 9-Aerosil 200Pharma 9-Silica 1.00 Phase B. Phase B. Phase B. 9-N-Zorbit M 9-TapiocaMaltodextrin 20.00 10-Flavor 10--Flavor 0.50 Total 100.00Additional ingredients or substitutions can be chosen from the listbelow.

1—Food Starch Modified, Bulking, and/or functional agents:

-   -   Tapioca Maltodextrin.    -   Wheat Dextrin    -   Waxy Maize    -   Tapioca Starch    -   Film Formers

Firming Agents

Flavor Carriers

Gelling Agents

Grain-Based Food Ingredients

Hydrolyzed Cereal Solids

Maltodextrins see also Bulking Agents; Encapsulated Ingredients

Meat Extenders

Oils, Vegetable, Corn

Starches, Corn, Dusting, Modified, Pregelatinized, Thin Boiling

Tableting Agents

Standard Stabilizing Gums such as: Agar, Alginates, Acacia, Carrageenan,Carboxymethyl Cellulose (CMC), hydroxypropyl methylcellulose,microcrystalline cellulose, and methylcellulose, Locust bean gum, Guar(endosperm of the plant Cyamopsis tetragonoloba), Inulin (occurringdietary fiber that can be extracted from the chicory root and Jerusalemartichokes.), Pectin (Pectin is extracted from the peels of citrusfruit), Xantam Gum, Gum Arabic.

Nutraceutical Ingredients: include any kind of natural, and/or syntheticingredients which may establish a link between food and health in humansand/or animals. It may include ingredients obtained from fruits, herbs,marines, spices, vegetables and synthetically formed compounds. Thesegroups include, yet are not limited to, the following ingredients:isoflavones, lecithin, oils and fats (low trans-fat oils), plantsterols, soy proteins, vitamins, Vitamin E, and mixed tocopherols

Flavors: any natural and/or synthetic flavors might be incorporated intothe composition. Flavor might be used in order to encourage use ofcomposition.

1. A method of treating or preventing glycation-related conditions,comprising, administering to a human or animal an effective amount of ananti-glycation composition comprising a mineral extract composition or amogroside/mineral extract composition or a mogroside composition,wherein the amount is effective in reducing at least a portion of theglycation events in a human or animal.
 2. The method of claim 1, whereinthe composition comprises a mineral extract composition.
 3. The methodof claim 1, wherein the composition comprises a mogroside/mineralextract composition.
 4. The method of claim 1, wherein the compositioncomprises a mogroside composition.
 5. The method of claim 1, wherein thecomposition further comprises a foodstuff.
 6. The method of claim 1,wherein the composition further comprises a beverage.
 7. The method ofclaim 1, wherein the glycation-related conditions comprise formation ofglycation end products, AGE formation, glycation reactions of proteins,lipids and/or nucleic acids, aging effects related to glycationreactions, and complications of diabetes (Type I and II), rheumatoidarthritis, Alzheimer's disease, uremia, neurotoxicity, atherosclerosis,inflammatory reactions, ventricular hypertrophy, angiopathy,myocarditis, nephritis, arthritis, glomerulonephritis,microangiopathies, and renal insufficiency, or accumulation of glycationproducts.
 8. An anti-glycation composition comprising mogroside and amineral extract composition.
 9. The composition of claim 8, furthercomprising a foodstuff or beverage.
 10. The composition of claim 8,further comprising a sweetener composition.
 11. The anti-glycationcomposition of claim 8, wherein the composition comprises mogroside andis used for energy production.
 12. The anti-glycation composition ofclaim 8, wherein the composition comprises a mineral extract compositionwherein the composition is used for energy production.
 13. A method ofinhibiting glycation reactions, comprising, a) providing an effectiveamount of an anti-glycation composition comprising a mineral extractcomposition or a mogroside/mineral extract composition or a mogrosidecomposition, and b) inhibiting a glycation reaction.
 14. The method ofclaim 13, wherein the composition comprises a mineral extractcomposition.
 15. The method of claim 13, wherein the compositioncomprises a mogroside/mineral extract composition.
 16. The method ofclaim 13, wherein the composition comprises a mogroside composition. 17.The method of claim 13, wherein the composition further comprises afoodstuff.
 18. The method of claim 13, wherein the composition furthercomprises a beverage.
 19. The method of claim 13, wherein thecomposition is provided in vivo to a human or animal.
 20. The method ofclaim 13, wherein the composition is provided in vitro.